Testosterone supplementation therapy for men with hypogonadism remains controversial. The definition of hypogonadism in older men is vague and many of the associated symptoms could be considered to be physiological and not requiring treatment. In this Perspectives, Laurence Klotz considers the evidence—or lack thereof—to support the safety of TST in men with and without prostate cancer, and recommends caution in its use.
